Icotrokinra, a targeted oral peptide that selectively binds the interleukin-23 receptor, is under investigation for the ...

The global psoriasis treatment market is projected to expand at a compound annual growth rate (CAGR) of 8.5% by 2026. Key factors fueling this growth include the rising prevalence of psoriasis, ...

Following the NDA submission for icotrokinra treatment of adults and adolescents with moderate to severe plaque psoriasis to ...

Results of a meta-analysis showed that all biologic agents were superior to placebo for improving short-term outcomes in moderate to severe plaque psoriasis.

Greater rates of patients with PsO achieved concurrent complete skin and nail clearance with bimekizumab vs adalimumab, ustekinumab, and secukinumab.

Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing ...

On November 6, 2025, Hikma Pharmaceuticals PLC, and its subsidiary Hikma Pharmaceuticals USA Inc., announced the launch of ...

Subgroup analyses from one of the agent's pivotal trials showed that 29.5% of adolescents receiving icotrokinra achieved PASI 100, reflecting 100% improvement on the Psoriasis Area and Severity Index, ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing endoscop ...

Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favourable safety profile in difficult-to-treat scalp and genital psoriasis ...

Johnson & Johnson (NYSE: JNJ) today announced new long-term 52-week data from the Phase 3 ICONIC-TOTAL studya evaluating icotrokinra, a first-in-class investigational targeted oral peptide that ...